 Tissue Plasminogen Activator
"Tissue Plasminogen Activator" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A proteolytic enzyme in the serine protease family found in many tissues which converts PLASMINOGEN to FIBRINOLYSIN. It has fibrin-binding activity and is immunologically different from UROKINASE-TYPE PLASMINOGEN ACTIVATOR. The primary sequence, composed of 527 amino acids, is identical in both the naturally occurring and synthetic proteases.
| Descriptor ID |
D010959
|
| MeSH Number(s) |
D08.811.277.656.300.760.875 D08.811.277.656.959.350.875 D12.776.124.125.662.768 D23.119.970
|
| Concept/Terms |
Tissue Plasminogen Activator- Tissue Plasminogen Activator
- Plasminogen Activator, Tissue
- Tissue Activator D-44
- Tissue Activator D 44
- Tisokinase
- Tissue-Type Plasminogen Activator
- Tissue Type Plasminogen Activator
- TTPA
- T-Plasminogen Activator
- T Plasminogen Activator
- Alteplase
- Plasminogen Activator, Tissue-Type
- Plasminogen Activator, Tissue Type
Activase- Activase
- Hoffmann-La Roche Brand of Alteplase
- Hoffmann La Roche Brand of Alteplase
- Genentech Brand of Alteplase
- Alteplase Genentech Brand
Actilyse- Actilyse
- Boehringer Ingelheim Brand of Alteplase
- Lysatec rt-PA
- Lysatec rt PA
- Lysatec rtPA
- Promeco Brand of Alteplase
- Alteplase Promeco Brand
|
Below are MeSH descriptors whose meaning is more general than "Tissue Plasminogen Activator".
Below are MeSH descriptors whose meaning is more specific than "Tissue Plasminogen Activator".
This graph shows the total number of publications written about "Tissue Plasminogen Activator" by people in this website by year, and whether "Tissue Plasminogen Activator" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1988 | 1 | 0 | 1 | | 1992 | 1 | 0 | 1 | | 1994 | 1 | 0 | 1 | | 1995 | 0 | 1 | 1 | | 1996 | 1 | 0 | 1 | | 1999 | 0 | 2 | 2 | | 2000 | 2 | 2 | 4 | | 2001 | 1 | 0 | 1 | | 2002 | 3 | 2 | 5 | | 2003 | 2 | 1 | 3 | | 2004 | 2 | 4 | 6 | | 2005 | 2 | 4 | 6 | | 2006 | 1 | 4 | 5 | | 2007 | 1 | 2 | 3 | | 2008 | 6 | 0 | 6 | | 2009 | 1 | 0 | 1 | | 2010 | 2 | 1 | 3 | | 2011 | 3 | 0 | 3 | | 2012 | 1 | 1 | 2 | | 2013 | 3 | 3 | 6 | | 2014 | 2 | 1 | 3 | | 2015 | 5 | 0 | 5 | | 2016 | 3 | 0 | 3 | | 2017 | 2 | 1 | 3 | | 2018 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Tissue Plasminogen Activator" by people in Profiles.
-
Naragum V, Jindal G, Miller T, Kole M, Shivashankar R, Merino JG, Cole J, Chen R, Kohler N, Gandhi D. Functional Independence After Stroke Thrombectomy Using Thrombolysis In Cerebral Infarction Grade 2c: A New Aim of Successful Revascularization. World Neurosurg. 2018 Nov; 119:e928-e933.
-
Mueller-Kronast NH, Zaidat OO, Froehler MT, Jahan R, Aziz-Sultan MA, Klucznik RP, Saver JL, Hellinger FR, Yavagal DR, Yao TL, Liebeskind DS, Jadhav AP, Gupta R, Hassan AE, Martin CO, Bozorgchami H, Kaushal R, Nogueira RG, Gandhi RH, Peterson EC, Dashti SR, Given CA, Mehta BP, Deshmukh V, Starkman S, Linfante I, McPherson SH, Kvamme P, Grobelny TJ, Hussain MS, Thacker I, Vora N, Chen PR, Monteith SJ, Ecker RD, Schirmer CM, Sauvageau E, Abou-Chebl A, Derdeyn CP, Maidan L, Badruddin A, Siddiqui AH, Dumont TM, Alhajeri A, Taqi MA, Asi K, Carpenter J, Boulos A, Jindal G, Puri AS, Chitale R, Deshaies EM, Robinson DH, Kallmes DF, Baxter BW, Jumaa MA, Sunenshine P, Majjhoo A, English JD, Suzuki S, Fessler RD, Delgado Almandoz JE, Martin JC, Haussen DC. Systematic Evaluation of Patients Treated With Neurothrombectomy Devices for Acute Ischemic Stroke: Primary Results of the STRATIS Registry. Stroke. 2017 10; 48(10):2760-2768.
-
Lisabeth LD, Baek J, Morgenstern LB, Reeves MJ, Brown DL, Zahuranec DB, Smith MA, Sánchez BN. Sex differences in the impact of acute stroke treatment in a population-based study: a sex-specific propensity score approach. Ann Epidemiol. 2017 08; 27(8):493-498.e2.
-
Salerno A, Cotter BV, Winters ME. The Use of Tissue Plasminogen Activator in the Treatment of Wallenberg Syndrome Caused by Vertebral Artery Dissection. J Emerg Med. 2017 May; 52(5):738-740.
-
Domino JS, Baek J, Meurer WJ, Garcia N, Morgenstern LB, Campbell M, Lisabeth LD. Emerging temporal trends in tissue plasminogen activator use: Results from the BASIC project. Neurology. 2016 Nov 22; 87(21):2184-2191.
-
Middleton S, Levi C, Dale S, Cheung NW, McInnes E, Considine J, D'Este C, Cadilhac DA, Grimshaw J, Gerraty R, Craig L, Schadewaldt V, McElduff P, Fitzgerald M, Quinn C, Cadigan G, Denisenko S, Longworth M, Ward J. Triage, treatment and transfer of patients with stroke in emergency department trial (the T3 Trial): a cluster randomised trial protocol. Implement Sci. 2016 10 18; 11(1):139.
-
Rossi KC, Liang JW, Wilson N, Tuhrim S, Dhamoon MS. More Time Is Taken to Administer Tissue Plasminogen Activator in Ischemic Stroke Patients with Earlier Presentations. J Stroke Cerebrovasc Dis. 2017 Jan; 26(1):70-73.
-
Carandang RA. Thirty Years After the National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Trial: A New Era for Stroke Therapy. JAMA Neurol. 2016 Mar; 73(3):265-7.
-
Masrur S, Cox M, Bhatt DL, Smith EE, Ellrodt G, Fonarow GC, Schwamm L. Association of Acute and Chronic Hyperglycemia With Acute Ischemic Stroke Outcomes Post-Thrombolysis: Findings From Get With The Guidelines-Stroke. J Am Heart Assoc. 2015 Sep 25; 4(10):e002193.
-
Burlage LC, Karangwa SA, Lisman T, Martins PN, Porte RJ. Thrombolytic protocol minimizes ischemic-type biliary complications in liver transplantation from donation after circulatory death donors. Liver Transpl. 2015 Sep; 21(9):1231-2.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|